3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
23
Phase 1
15
Phase 1/2
10
Phase 3
9
Phase EARLY_PHASE1
2
Phase NA
1
Phase 4
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Melanoma
3
Neoplasms
2
Skin Neoplasms
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Kidney Neoplasms
1
Carcinoma, Renal Cell
1
Interventions
Sunitinib
5
Everolimus
5
Nivolumab
4
pazopanib
3
cabozantinib
2
aldesleukin
2
palbociclib
1
olaparib
1
lenvatinib
1
Zoledronic Acid
1
Tobacco Use Cessation Devices
1
Standard of Care
1
Specimen Handling
1
Sorafenib
1
Single Person
1
Radiotherapy
1
Psychiatric Rehabilitation
1
Polymerase Chain Reaction
1
Nutrition Therapy
1
Midazolam
1
Ipilimumab
1
Interferons
1
Immune Checkpoint Inhibitors
1
High-Energy Shock Waves
1
Gene Expression Profiling
1
Gemcitabine
1
Erlotinib Hydrochloride
1
Early Intervention, Educational
1
Counseling
1
Caffeine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
Carcinoma, Renal Cell
×
Ipilimumab
×
Clear all
NCT02982954
2022-11-01
CHECKMATE 920
Bristol-Myers Squibb
Phase 4
Completed
211 enrolled
21 charts